Abstract 387P
Background
Preliminary data suggest that combining savolitinib (AZD6094, HMPL-504, volitinib), a potent and highly selective MET-tyrosine kinase inhibitor (TKI), with osimertinib, a 3rd generation, irreversible, oral epidermal growth factor receptor (EGFR) TKI that potently and selectively inhibits both EGFR mutations (EGFRm) and EGFR T790M, may overcome MET-driven resistance to EGFR-TKIs. The maximum tolerated dose (MTD) of savolitinib regimens in Japanese pts was evaluated in Part C of the phase Ib, multi-arm, open-label, multicenter TATTON study (NCT02143466).
Methods
Two dose-finding cohorts of pts (≥20 years) received savolitinib monotherapy (pts with advanced solid malignancies; savolitinib 400/600 mg once daily [QD]) or savolitinib/osimertinib combination therapy (pts with EGFRm non-small cell lung cancer [NSCLC] who progressed on 1st/2nd-generation EGFR-TKI; osimertinib 80 mg + savolitinib 300/400/600 mg QD). Primary endpoints were safety/tolerability and to define the combination dose(s) for further clinical evaluation. Secondary endpoints for combination included evaluation of tumor response.
Results
Seventeen pts received savolitinib monotherapy (400 mg, n=7/17; 600 mg, n=10/17) and 12 received the combination (savolitinib dose 300 mg, n=2/12; 400 mg, n=6/12; 600 mg, n=4/12). Serious adverse events (AE) were reported in 5/17 and 3/12 of pts, and AEs possibly causally related to savolitinib leading to its discontinuation were reported in 3/17 and 6/12 respectively. Dose-limiting toxicities data are included in the table, all except one were reversible. Pts receiving the combination (across doses) had an objective response rate of 42% (95% confidence interval 15.2, 72.3).
Conclusions
The MTD of savolitinib was 400 mg QD in both monotherapy and combination cohorts. Preliminary data demonstrate an acceptable safety profile for savolitinib and suggest antitumor activity in combination with osimertinib in Japanese pts with EGFRm NSCLC Table: 387P
Dose | Evaluable patients with DLT | DLT* |
Monotherapy | ||
Savolitinib 400 mg | 0/6 | |
Savolitinib 600 mg | 3/9 | Grade 3 ALT increase, Grade 3 AST increase |
Grade 4 ALT increase, Grade 4 AST increase | ||
Grade 4 drug-induced liver injury# | ||
Combination therapy | ||
Savolitinib 300 mg + Osimertinib 80 mg | 0/2 | |
Savolitinib 400 mg + Osimertinib 80 mg | 1/6 | Grade 2 fatigue, Grade 2 nausea, Grade 2 myalgia |
Savolitinib 600 mg + Osimertinib 80 mg | 3/4 | Grade 2 pyrexia† |
Grade 3 skin reaction | ||
Grade 3 anaphylactic shock† |
*n=1 for all events #Not recovered/not resolved †Guidelines are now in place regarding hypersensitivity-related AEs ALT, alanine aminotransferase; AST, aspartate aminotransferase; DLT, Dose-limiting toxicity
.Clinical trial identification
NCT02143466.
Editorial acknowledgement
Bernadette Tynan, MSc, of Ashfield Healthcare Communications, Macclesfield, UK, for medical writing support that was funded by AstraZeneca, Cambridge, UK, in accordance with Good Publications Practice (GPP3) guidelines.
Legal entity responsible for the study
AstraZeneca.
Funding
AstraZeneca.
Disclosure
T. Hirashima: Honoraria (self), Research grant/Funding (self): Ono Pharmaceutical Co. Ltd; Honoraria (self), Research grant/Funding (self): Lilly Japan Co. Ltd.; Honoraria (self), Research grant/Funding (self): AstraZeneca Co. Ltd.; Honoraria (self), Research grant/Funding (self): Taiho Pharmaceutical Co. Ltd.; Honoraria (self), Research grant/Funding (self): Chugai Pharmaceutical Co. Ltd.; Honoraria (self), Research grant/Funding (self): MSD Oncology Co.; Honoraria (self), Research grant/Funding (self): Boehringer Ingelheim; Research grant/Funding (self): Merck Serono Co. Ltd. K. Yoh: Honoraria (self): Chugai Pharma; Honoraria (self): AstraZeneca; Honoraria (self): Lilly Japan; Honoraria (self): Novartis; Honoraria (self): Kirin; Honoraria (self): Bristol-Myers Squibb Japan; Honoraria (self): Taiho. H. Saka: Honoraria (self), Research grant/Funding (self): AstraZeneca. T. Kurata: Honoraria (self), Research grant/Funding (self): AstraZeneca; Honoraria (self): Eli lilly; Honoraria (self), Research grant/Funding (self): MSD; Honoraria (self): Ono; Honoraria (self): Boehringer Ingelheim; Honoraria (self): Chugai; Honoraria (self), Research grant/Funding (self): Bristol-Myers; Research grant/Funding (self): Takeda; Research grant/Funding (self): Novartis. Y. Ohe: Honoraria (self), Advisory/Consultancy, Research grant/Funding (self): AstraZeneca, Chugai, ONO, Bristol-Myers Squibb; Research grant/Funding (self): Takeda; Advisory/Consultancy, Research grant/Funding (self): Kyorin; Advisory/Consultancy: Celltrion; Advisory/Consultancy: Amgen; Advisory/Consultancy: Nippon Kayaku; Honoraria (self): Eli Lilly; Honoraria (self): Boehringer Ingelheim; Honoraria (self): Bayer; Honoraria (self), Research grant/Funding (self): Pfizer; Honoraria (self): MSD; Honoraria (self), Research grant/Funding (self): Taiho; Honoraria (self): Nippon Kayaku; Honoraria (self): Kyowa Hakko Kirin; Research grant/Funding (self): Lilly; Research grant/Funding (self): Dainippon- Sumitomo; Research grant/Funding (self): Novartis; Research grant/Funding (self): Ignyta; Research grant/Funding (self): Kissei; Research grant/Funding (self): Daiichi-Sankyo, Janssen, Loxo. T. Hida: Honoraria (self): Ono Pharmaceutical; Honoraria (self): Chugai Pharmaceutical; Honoraria (self): AstraZeneca; Honoraria (self): Bristol-Meyers Squibb; Honoraria (self): MSD; Honoraria (self): Pfizer; Honoraria (self): Novartis. A. Mellemgaard: Full/Part-time employment: AstraZeneca. R.B. Verheijen: Shareholder/Stockholder/Stock options, Full/Part-time employment: AstraZeneca; Full/Part-time employment: Johnson&Johnson; Shareholder/Stockholder/Stock options: Aduro Biotech. X. Ou: Full/Part-time employment, Contracted with AstraZeneca through Phastar: AstraZeneca. M. Hayama, K. Sugibayashi: Shareholder/Stockholder/Stock options, Full/Part-time employment: AstraZeneca. G. Oxnard: Honoraria (self): Foundation Medicine; Honoraria (self): Guardant Health; Honoraria (self): Sysmex; Advisory/Consultancy: AbbVie; Advisory/Consultancy: AstraZeneca; Advisory/Consultancy: DropWorks; Advisory/Consultancy: GRAIL; Advisory/Consultancy: Illumina; Advisory/Consultancy: Inviata; Advisory/Consultancy: Janssen; Advisory/Consultancy: Loxo; Advisory/Consultancy: Takeda; Licensing/Royalties, DCFI patent describing blood-based cancer monitoring: DFCI; Full/Part-time employment, Commencing June 15th: Foundation Medicine.
Resources from the same session
153P - Mutational landscape of gastric cancer (GC) in adolescents and young adults (AYA) in Asia from 2015-2019
Presenter: Evelyn Yi Ting Wong
Session: e-Poster Display Session
154P - A multicenter, prospective study of apatinib plus chemotherapy as neoadjuvant treatment for locally advanced gastric cancer
Presenter: Yi-Hui Tang
Session: e-Poster Display Session
155P - Surgical outcomes and technical performance of robotic versus laparoscopic total gastrectomy for gastric cancer: A prospective comparative study FUGES-014
Presenter: Hua-Gen Wang
Session: e-Poster Display Session
156P - Safety and feasibility of laparoscopic spleen-preserving splenic hilar lymphadenectomy during total gastrectomy for advanced proximal gastric cancer: A randomized clinical trial
Presenter: Jian-Xian Lin
Session: e-Poster Display Session
157P - Efficacy and safety of penpulimab (AK105), a new generation anti-programmed cell death-1 (PD-1) antibody, in upper gastrointestinal cancers
Presenter: Amy Prawira
Session: e-Poster Display Session
158P - A phase II study of trastuzumab with S-1 plus oxaliplatin for HER2-positive advanced gastric cancer (HIGHSOX study): Final report
Presenter: Atsuo Takashima
Session: e-Poster Display Session
159P - Open surgery can improve the 3-year postoperative survival in some patients with advanced gastric cancer compared with laparoscopic surgery: A multicenter, propensity score matching, in-depth analysis
Presenter: Ze-Ning Huang
Session: e-Poster Display Session
160P - Phase II study of sintilimab combined with FLOT regimen for neoadjuvant treatment of gastric or gastroesophageal junction (GEJ) adenocarcinoma
Presenter: Ning Li
Session: e-Poster Display Session
161P - Adjuvant tegafur/gimeracil/oteracil (S-1) versus platinum-based chemotherapies for resectable gastric cancer: Real-world experience and a propensity score matching analysis
Presenter: Chih Chieh Yen
Session: e-Poster Display Session
162P - Evaluation of neutrophil/lymphocyte ratio (NLR) in monitoring anastomotic leakage after radical total gastrectomy for gastric cancer
Presenter: Ru-Hong Tu
Session: e-Poster Display Session